Rheumatoid arthritis (RA) is a systemic autoimmune disease that primarily causes chronic inflammation of the joints. One of the hallmarks of RA is the activation of the cells that make up the synovial lining of affected joints. [1] [2] [3] During RA, the normally thin synovial lining becomes dramatically thickened and hyperplastic due to persistent secretion of inflammatory cytokines such as IL-1 and TNF-a by macrophages and synoviocytes. [4] [5] [6] [7] The expanded synovium becomes aggressive and gradually invades and erodes the articular cartilage and bone, eventually resulting in loss of joint function. In many respects the phenotype of the RA synovium is similar to that of an aggressive tumor. 1, 8 An analysis of tissue from RA patients suggests that a disruption in the control of the cell cycle or apoptotic pathways may be the cause of the abnormal expansion of cells observed in the rheumatoid synovium. 9, 10 This raises the possibility that the delivery of molecules that induce apoptosis to diseased joints may result in a retardation or regression of the aggressive synovium.
One approach to treating the hyperplastic synovial tissue is through intra-articular gene transfer of apoptotic agents to RA joints, resulting in a molecular synovectomy. We have previously demonstrated that adenoviralmediated delivery of the FasL or TNF-a (Lechman et al, unpublished) results in the induction of apoptosis of the cells of the synovial lining in a rabbit knee model of arthritis. 11, 12 However, the toxicity associated with these TNF family members will likely limit their utility in clinical applications. Similarly, we have demonstrated that intra-articular gene transfer of p53 results in extensive apoptosis. 12 The TNF-related apoptosis-inducing ligand (TRAIL) is a recently described member of the TNF superfamily that has been reported to selectively induce apoptosis in transformed cells. [13] [14] [15] Given the transformed nature of the synovium in RA joints, it seems possible that TRAIL may offer a safe molecule that can be utilized for the ablation of the rheumatoid synovium. TRAIL is a type II transmembrane protein of the TNF-a superfamily that was initially discovered due to its sequence homology with TNF-a and FasL. 13, 14 Similar to FasL and TNF-a, TRAIL has demonstrated the ability to induce a potent apoptotic response in susceptible cells. 16 TRAIL induces apoptosis by binding to and cross-linking death-domain containing receptors, TRAIL-R1 (DR4) and TRAIL-R2 (DR5). 14, [17] [18] [19] [20] [21] In addition to these active receptors, several decoy receptors for TRAIL that lack active death domains have been identified (TRAIL-R3, TRAIL-R4 and OPG). 19, [22] [23] [24] [25] [26] While it has been postulated that these decoy receptors may play a role in the regulation of TRAIL mediated apoptosis no correlation between TRAIL susceptibility and the expression of decoy receptors was found in a screen of primary human melanoma and myeloma cell lines. 17, 27 The intriguing aspect to TRAIL-induced apoptosis is that TRAIL has a potent cytotoxic effect on a number of human tumor cells, but generally has no effect on the viability of normal cells. 13, 14 The ability of TRAIL to selectively induce apoptosis in transformed cells makes it more attractive as an apoptosis-inducing agent than other pro-apoptotic proteins such as FasL and TNFa that, in addition to their strong anti-tumor effects, have severe toxic side effects. Given that the activated synovium in RA joints displays many attributes similar to that observed in transformed cells, we were interested in examining the effect of overexpressing TRAIL on arthritic synoviocytes.
In order to deliver TRAIL to synovial cells both in culture and in vivo, a replication defective adenoviral vector carrying the cDNA for human TRAIL was generated. The recombinant adenoviral vector was derived from a replication-deficient type 5 adenovirus lacking the E1 and E3 loci. 28 The human TRAIL or the bacterial b-galactosidase cDNAs were inserted in place of the E1 region, and expression driven by the human cytomegalovirus immediate early promoter (CMV). Expression of TRAIL from the vector was confirmed by Western analysis following infection of HIG-82 cells and primary human synovial cells (Figure 1a ). Cells infected with Ad.TRAIL displayed an immunoreactive band of approximately 32 kD that was absent from extracts derived from cells treated with a LacZ control vector, indicating that full-length TRAIL product was being produced following infection of synovial cells with the Ad.TRAIL vector.
To examine the ability of TRAIL to induce apoptosis in RA synovial cells, primary cell lines generated from the synovium of RA patients were infected with either the Ad.TRAIL or Ad.LacZ vector at increasing viral doses. The extent of apoptosis was determined by measuring the level of release of LDH, a marker of cell death. As shown in Figure 1b , Ad.TRAIL infection was able to stimulate cell death. Infection of the synovial cell lines with Ad.TRAIL at an MOI of 100 resulted in significant cell death, as monitored by LDH release, in three of the five cell lines tested relative to a similar dose of Ad.LacZ. The sensitive lines displayed a 180% increase in LDH release relative to Ad.LacZ-infected cells with a high of 273% and a low of 120%. Lines 4 and 5 displayed no significant differences in LDH release between Ad.LacZand Ad.TRAIL-infected cells and were considered TRAIL insensitive at the doses tested. Similar results were obtained using an MTT assay to measure cell viability as well as by TUNEL analysis to demonstrate that Ad.TRAIL infection was inducing apoptosis (data not shown; see Figure 2b ). The reason for the selective sensitivity of the different cell lines is unclear, but appears to be unrelated to the presence of TRAIL receptors as no correlation between the level of TRAIL-R1 (DR4) or TRAIL-R2 (DR5) was observed (data not shown).
The cytotoxic effect observed following TRAIL gene transfer in synovial fibroblasts isolated from RA patients suggested that TRAIL expression might be able to induce apoptosis in cells within the synovial lining of the arthritic joint. To test this hypothesis, the effect of Ad.TRAIL infection was examined in the knee joints of rabbits with experimental, IL-1b induced arthritis. This particular animal model was chosen because the rabbit knee is similar in size to many human joints commonly affected by RA. To first confirm that human TRAIL would stimulate apoptosis in rabbit synovial fibroblasts, similar to human cells, fibroblasts were cultured from tissues obtained from rabbit knees with arthritis induced by constitutive, intra-articular over-expression of IL-1b. Subsequently, Ad.TRAIL or Ad.LacZ was used to infect the cell cultures at an MOI of 100. forty-eight hours postinfection the amount of cell death was determined using the LDH assay (Figure 2a ) as well as an MTT assay (data not shown). To demonstrate that Ad.TRAIL infection was able to induce apoptotis, the percentage of cells undergoing apoptosis following infection was examined by TUNEL staining. As shown in Figure 2b , approximately 90% of the Ad.TRAIL-infected cells were TUNEL positive as compared to the control, Ad.LacZ-infected cells. Taken together, these results suggest that rabbit synovial fibroblasts displayed sensitivity to Ad.TRAIL infection, similar to three of the five primary human cell lines. Interestingly, a greater induction of apoptosis was observed in Ad.TRAIL-infected rabbit synovial cells than was observed in human RA cells. Infection of cells with an MOI of 100 resulted in greater than a 90% cytotoxic effect in rabbit cells whereas a similar dose of vector resulted in only 35% cell death, determined by LDH, MTT and TUNEL analysis, in the most sensitive human cell line. The reason as to why the rabbit cells are more sensitive than human cells to Ad.TRAIL infection is unclear at this time.
To assess the effect of intra-articular expression of TRAIL on arthritic synovium, Ad.TRAIL was injected TRAIL and arthritis Q Yao et al observed in rheumatoid arthritis, including hyperplasia of the synovium, leukocytosis of the synovial fluid and aggressive pannus formation. Four days post-induction of arthritis, the knee joints of all rabbits were lavaged with saline and the infiltrating leukocytes counted to establish a pretreatment baseline. Immediately following the lavage, Ad.TRAIL was delivered to the knee joints of the rabbits by intra-articular injection. As a control for the effects of adenoviral infection, Ad.LacZ was injected into both knees of parallel groups of animals. A third group of animals was injected with an equal volume of saline. At 1, 2 and 4 days post-injection of the vectors, the knee joints of all animals were lavaged with saline. At day 4 the animals were sacrificed to allow for analysis of the joint tissues. The joints of the sacrificed animals were surgically dissected and the synovium harvested and fixed for paraffin embedding. Cartilage explants were also taken from the tibial plateau and femoral chondyles, and used for glycosaminoglycan synthesis assays in order to monitor the effect of treatment on cartilage synthesis.
Following sacrifice of the animals and dissection of joint capsules, no apparent macroscopic differences in the physical appearance of the intra-articular surfaces of the joints were observed between the groups of animals. All joints displayed a similarly severe, aggressive synovitis typical of the model. In contrast, examination of the synovial tissues at the microscopic level revealed discrete differences between the tissues harvested from the different experimental groups. In the control groups, Ad.LacZ and saline (data not shown), the synovial tissues remained thickened and highly cellular, with regions of lymphocytic accumulation (Figure 3a) . In contrast, the Ad.TRAIL-treated animals displayed discrete regions of synovium that were comprised mainly of acellular matrix (Figure 3c ). These regions of reduced cellularity were focal in nature, involving between 20% and 75% of the synovial tissue within the experimental group. While some of the acellular areas were quite extensive and extended deep into the grossly thickened synovium, other fields appeared less affected and more similar to the saline and Ad.LacZ controls. TUNEL staining was performed on serial tissue sections from the treated joints to examine if the acellular regions of the Ad.TRAIL-treated tissue were associated with apoptotic death of the resident cells of the synovium. Staining of tissue harvested from Ad.LacZ-treated joints displayed few tunel-positive nuclei (Figure 3b ). In contrast, Figure 3 Over expression of adenoviral-mediated TRAIL in the synovium induces synovial hypocellularity and apoptosis. Three days post-induction of arthritis in rabbit knee joints, the knees were injected intra-articularly in both knees with 0.25 ml saline or saline containing 1 Â 10 11 particles of Ad.LacZ or Ad.TRAIL. Four days post-injection of the adenoviral vectors, the animals were sacrificed and the synovial capsules harvested. Tissue was fixed and serial paraffin-embedded sections were taken and stained with hematoxylin and eosin (H&E; panels a and c). Similar sections were also stained by TUNEL to detect the presence of apoptotic cells (panels b and d).
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Q Yao et al TUNEL-stained sections harvested from Ad.TRAILtreated joints displayed a high number of TUNELpositive nuclei indicating apoptotic cell death ( Figure  3d ). To determine if the delivery of Ad.TRAIL had any effect on the inflammation in arthritic joints, we analyzed the degree of white blood cell (WBC) infiltration into the synovial fluid before and after vector treatment ( Figure  4a ). The joints treated with Ad.TRAIL displayed a small, but consistent reduction in inflammation relative to control joints treated with either saline or Ad.LacZ. This reduction was most obvious at 2 days following vector delivery where Ad.TRAIL-treated joints showed a 44% and 60% reduction in inflammation relative to Ad.LacZand saline-treated joints. However, by day four this reduction had been reduced to 19% and 30% respectively and was no longer statistically significant. Thus there appears not to be a specific type of infiltrating cell type that was suppressed by intra-articular Ad.TRAIL gene transfer. In addition, analysis of the cartilage shavings for GAG synthesis showed that Ad.TRAIL gene transfer resulted in an increase in new matrix synthesis by the cartilage, compared to control arthritic joints (Figure 4b ). This result demonstrates that intra-articular TRAIL gene expression does not adversely affect chondrocyte viability. Moreover, this result suggests that TRAILmediated synovial apoptosis and/or the decrease in the WBC infiltrate results in improvement in cartilage metabolism.
This report represents the first indication that TRAIL can affect the viability of the cell populating the synovium in arthritic joints. This observation is interesting in that it suggests that the cells residing in the arthritic synovium are modified through an unknown mechanism to be sensitive to TRAIL whose cytotoxic effect has been reported to be limited to tumor cells. The study described here was designed to assess the potential of TRAIL as an agent for ablating RA synovium in vivo. Based on the results obtained in these limited experiments, it seems that TRAIL may be a promising reagent for this application in that three out of five of the human synovial cell lines tested displayed sensitivity to TRAIL gene transfer. Furthermore, Ad.TRAIL delivery to arthritic synovium in a rabbit model of RA resulted in significant apoptosis within the arthritic synovium. Importantly, unlike our previous results with FasL and TNF-alpha, the induction of apoptosis by TRAIL gene transfer was not associated with an increase in inflammation within the joint. Rather, Ad.TRAIL-treated joints displayed a small, but consistent reduction in inflammation relative to controls. While we have utilized adenoviral vector mediated, intra-articular overexpression of TRAIL, it is also possible that the use of recombinant TRAIL protein for intra-articular injection may be effective. Indeed, preliminary experiments suggest that intra-articular injection of rTRAIL is able to induce synovial apoptosis in the rabbit model of arthritis, although not as efficiently as adenoviralmediated gene transfer of TRAIL. Taken together, our results suggest that TRAIL is able to induce apoptosis of hyperplastic human RA synovial fibroblasts in culture and rabbit synovial tissue in vivo, conferring significant therapeutic effects in a rabbit knee model of arthritis. These results clearly warrant further development of TRAIL gene therapy for the treatment of pathologies associated with the progression of rheumatoid arthritis. Figure 4 (a) TRAIL overexpression reduces leukocytic infiltration into the synovial fluid. Analysis of the joint lavage was performed to monitor leukocytic infiltration into the synovial fluid of joints. one milliliter of Gey's balanced salt solution was delivered to the joint space by direct intraarticular injection through the patellar tendon. The joints were then manipulated through several ranges of motion to allow for mixing of the fluids and the needle reinserted to aspirate the fluid. The leukocytes in the recovered fluids were counted using a hemocytometer. (b) TRAIL overexpression stimulates glycosaminoglycan (GAG) synthesis of articular cartilage. Four days following intra-articular gene transfer, cartilage shavings were taken from the femoral condyles. Approximately 30 mg of cartilages from each joint was cut into small pieces and then incubated in 500 ml of DMEM with 40 mCi of 35 SO4
À2 at 37C1 for 24 h. The media were then recovered and stored at -201C. GAGs were extracted from the cartilage shavings by incubation in 0.5 ml of 0.5 M NaOH at 41C with gentle shaking for 24 h. Following chromatographic separation of unincorporated 35 SO4 À2 using PD-10 columns, radiolabeled GAGs released into the culture or recovered by alkaline extraction were quantitated using a scintillation counter. The CPM value of samples was transformed to % change in Ad.TRAIL treatment relative to 100% in Ad.LacZ control.
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